The complexity of biological systems often leaves pharmaceutical researchers grappling with a vast "dark matter" of untreatable conditions, where nearly 90% of human biology remains untouched by current therapeutic interventions. This systemic limitation has historically led to a high-risk and
While Chimeric Antigen Receptor (CAR) T-cell therapy has successfully transformed the clinical outlook for patients with liquid cancers, its efficacy against solid tumors remains one of the most significant hurdles in modern oncology. Unlike the accessible environment of the bloodstream, where
The pharmaceutical landscape is currently witnessing a high-stakes confrontation as Shanghai Henlius Biotech maneuvers to intercept Pfizer’s dominance in the next generation of lung cancer therapy. At the heart of this struggle is the development of antibody-drug conjugates (ADCs) targeting PD-L1,
Lukas Hainz sits down with Ivan Kairatov, a distinguished biopharma expert with a deep background in research and development and a keen eye for technological innovation within the pharmaceutical industry. Together, they explore a recent breakthrough from the University of Cambridge that reimagines
The global pharmaceutical landscape is currently navigating a period of intense pressure as the rise of multi-drug resistant pathogens outpaces the traditional speed of antibiotic development. For decades, the process of vetting new chemical entities has been a fragmented journey, requiring
The relentless pursuit of highly effective oncological interventions has historically been hampered by the inability of traditional pharmaceutical agents to distinguish accurately between malignant cells and healthy physiological structures. While chemotherapy and systemic radiation have saved
